Najmi Maleka, Tran Tiffaney, Witt Russell G, Nelson Kelly C
Department of Internal Medicine, Baylor Scott & White Medical Center, 2401 S 31st St MS-01-161B, Temple, TX, 76508, USA.
Baylor College of Medicine, Houston, TX, USA.
Dermatol Ther (Heidelb). 2022 Nov;12(11):2489-2497. doi: 10.1007/s13555-022-00810-1. Epub 2022 Sep 25.
For patients with metastatic melanoma, immunotherapy agents represent a promising treatment option, and researchers are actively seeking to identify factors that may predict a favorable response in patients. Recent studies have elucidated possible associations between the gut microbiome and the effects of immunotherapy, where variations in the gut microbiome may influence treatment response and frequency of adverse effects. In this clinical review, we describe the current literature related to the gut microbiome in the setting of immunotherapy, and we provide an overview of interventions under investigation that may modulate the gut microbiome. These interventions include fecal microbiota transplantation, probiotics, and dietary modifications.
对于转移性黑色素瘤患者，免疫治疗药物是一种有前景的治疗选择，研究人员正在积极寻找可能预测患者良好反应的因素。最近的研究阐明了肠道微生物群与免疫治疗效果之间可能存在的关联，其中肠道微生物群的变化可能会影响治疗反应和不良反应的发生率。在这篇临床综述中，我们描述了免疫治疗背景下与肠道微生物群相关的当前文献，并概述了正在研究的可能调节肠道微生物群的干预措施。这些干预措施包括粪便微生物群移植、益生菌和饮食调整。
